Equine Melanoma at a Glance
Melanoma Location Frequency
Comparison
| Feature | Benign Melanoma | Malignant Melanoma | Key Action |
|---|---|---|---|
| Growth Rate | Slow — months to years | Rapid — weeks | Biopsy if fast growth |
| Location | Perineum, tail, head | Internal (abdomen, nodes) | Ultrasound if suspected |
| Appearance | Firm, dark, smooth | Irregular, ulcerated | Surgical biopsy |
| Treatment | Monitor or surgical remove | Wide excision + imaging | Refer to equine surgeon |
Melanoma Management Flow
Melanoma Monitoring Checklist
| Document size and location of every mass | |
| Measure monthly and photograph for comparison | |
| Note any rapid growth or ulceration changes | |
| Schedule annual veterinary examination | |
| Biopsy any mass that changes rapidly | |
| Consider surgical removal if interfering with function | |
| Watch for weight loss or colic signs (internal spread) | |
| Discuss cimetidine or other medical therapy with vet |
Equine melanomas are tumors of melanocyte origin that develop in an estimated 70-80% of gray horses over age 15. Unlike melanoma in humans and dogs, which are typically malignant and life-threatening, equine melanomas in gray horses are usually slow-growing and benign for years. However, approximately 20% eventually undergo malignant transformation, invading deeper tissues and metastasizing. The most common locations: under the tail, around the anus and perineum, the parotid salivary gland region, and the external genitalia. Management ranges from watchful waiting to surgical excision to systemic treatment in progressive cases.
| Presentation | Risk Level | Action Threshold |
|---|---|---|
| Slow-growing stable nodules | Low — benign behavior | Annual size mapping and measurement; watchful waiting |
| Rapid growth, ulceration, or new atypical sites | Moderate — malignant concern | FNA or biopsy to assess malignant transformation |
| Internal or guttural pouch location | High — functional impact | Priority surgical or systemic treatment; affects swallowing and airway |
The Gray Horse Connection
The gray coat color gene causes progressive loss of melanocytes from the skin and hair follicles over time, producing the characteristic progressive graying from birth coat color to white. A side effect of this melanocyte disruption is abnormal melanocyte proliferation -- the same cells that are being lost from the hair follicles accumulate in other tissues, forming tumors. Gray horses are not born with tumors, but melanoma risk increases steadily with age. By age 15, approximately 80% of gray horses have at least one detectable melanoma. Breed predisposition: Arabians, Lipizzaners, Percheron Drafts, and Andalusians -- breeds with high gray frequency.
Where Equine Melanomas Form
Common locations in order of frequency: perianal and perineal region (most common -- found in the skin under and around the tail and anus), lips and muzzle, parotid salivary glands (visible swelling below the ear), prepuce and sheath in males, vulva in mares, external ear canal. Melanomas in these locations are usually palpable nodules ranging from pea-sized to baseball-sized. Multiple nodules are common. Critically concerning locations where even slow-growing melanomas cause serious problems: the guttural pouches (horse-specific pharyngeal air-filled structures near the skull base -- melanoma here impairs swallowing and airway), spinal cord regions (neurological signs), and mesentery (abdominal).
Monitoring: The Annual Exam Standard
Gray horses should have melanoma locations mapped and measured at annual or biannual veterinary exams. Growth rate, consistency (hard/nodular vs. ulcerated/soft), and any change in character are the key monitoring parameters. Slow growth of 1-5 mm per year over a stable period is typical benign behavior. Rapid growth, ulceration, pain, surrounding tissue invasion, or development of new nodules in atypical locations warrants further diagnostics (fine-needle aspirate or biopsy) to assess for malignant transformation.
Treatment Options
Small, accessible melanomas: surgical excision is curative if complete margins are achieved. Electrocoagulation (electrosurgery) and cryotherapy are alternatives for small lesions in accessible locations. Cimetidine (a histamine H2 receptor antagonist with immunomodulatory effects): some older reports suggest partial response rates, but controlled clinical evidence for efficacy is limited. Cisplatin intralesional injection: direct injection into tumor tissue achieves local control in some cases. Immunotherapy with autologous tumor antigen (tumor cells from the patient injected to stimulate immune response) shows promising results in research settings. Current best-evidence systemic option: a recombinant human DNA plasmid vaccine (xenogeneic DNA melanoma vaccine -- Oncept for dogs, off-label use being explored in horses) has shown some efficacy in preliminary equine studies.
Sources: Valentine BA. Equine melanomas. Veterinary Clinics of North America: Equine Practice 1995; Fleury C et al. The study of melanocyte biology and the gray horse. Pigment Cell Research 2000; Seltenhammer MH et al. Equine melanoma in a population of 296 gray Lipizzan horses. Equine Veterinary Journal 2003; Moore AS. Equine melanoma treatment review. AAEP Proceedings 2013.